{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:38:48Z","timestamp":1790689128173,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Triple combination of anti-PD-1\/PD-L1 immunotherapy and anti-BRAF plus anti-MEK targeted therapy is a promising antitumor strategy and is increasingly being used in clinical trials. To evaluate the safety and efficacy of triple combination of PD-1\/PD-L1, BRAF, and MEK inhibition in patients diagnosed with stage III-IV melanoma, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). The PubMed, EMBASE, and Cochrane Library were searched for all studies published from inception to January 2021. The progression free survival (PFS), overall survival (OS), overall response rate (ORR), and risk of adverse events (AEs) were extracted by two independent investigators and pooled hazard ratio (HR) or risk ratio (RR) with 95% CI were determined using the random-effects model for data synthesis. Overall, five randomized controlled trials encompassing 1,266 patients with stage III-IV melanoma were selected. Triple combination therapy significantly improved PFS (HR = 0.71; 95% CI = 0.59 to 0.86; P = 0.0005) and 2-year OS (RR = 1.12; 95% CI = 1.03 to 1.23; P = 0.01), but had no impact on ORR (RR = 1.09; 95% CI = 0.91 to 1.30; P = 0.37) when compared with controlled treatment group. In addition, triple combination therapy was associated with increased risks of hypothyroidism, arthralgia, myalgia, ALT increased, AST increased, asthenia, and pyrexia compared with control group. Triple combination therapy of PD-1\/PD-L1, BRAF, and MEK inhibition achieved better survival benefits but had higher incidence of some adverse events over two-drug combination or monotherapy. Further randomized controlled clinical trials are needed to verify our results.<\/jats:p><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO 2021 CRD42021235845 Available from <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021235845<\/jats:uri>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.693655","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T08:50:43Z","timestamp":1623660643000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Triple Combination Therapy With PD-1\/PD-L1, BRAF, and MEK Inhibitor for Stage III\u2013IV Melanoma: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Ye","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2017-0145","article-title":"New Strategies in Melanoma Therapy: Can Nanoparticles Overcome Chemoresistance","volume":"12","author":"Badea","year":"2017","journal-title":"Nanomedicine (Lond)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2014.11.006","article-title":"Recent Advances in Targeted Nanoparticles Drug Delivery to Melanoma","volume":"11","author":"Li","year":"2015","journal-title":"Nanomedicine"},{"key":"B4","article-title":"Membrane Transport Proteins Associated With Drug Resistance Expressed in Human Melanoma","volume":"147","author":"Schadendorf","year":"1995","journal-title":"Am J Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma Without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK Inhibition Versus BRAF Inhibition Alone in Melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31774","article-title":"Choice of First-Line Therapy in Metastatic Melanoma","volume":"125","author":"Gibney","year":"2019","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60972-2","article-title":"Inhibition of BRAF and MEK in BRAF-Mutant Melanoma","volume":"386","author":"Smalley","year":"2015","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2018.09.008","article-title":"Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A New Era in Cancer Active Immunotherapy","volume":"194","author":"Constantinidou","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab Versus Ipilimumab in Untreated Melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of Resistance to BRAF and MEK Inhibitors and Clinical Update of US Food and Drug Administration-Approved Targeted Therapy in Advanced Melanoma","volume":"11","author":"Kakadia","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000709","article-title":"Triplet Combination of BRAF, MEK and PD-1\/PD-L1 Blockade in Melanoma: The More the Better","volume":"33","author":"Trojaniello","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0181","article-title":"MEK Inhibition, Alone or in Combination With BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells","volume":"2","author":"Vella","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF Inhibition Is Associated With Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients With Metastatic Melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, Trametinib and Pembrolizumab or Placebo in BRAF-Mutant Melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK Inhibition With PD-1 Blockade Immunotherapy in BRAF-Mutant Melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1082-2","article-title":"Combined PD-1, BRAF and MEK Inhibition in Advanced BRAF-Mutant Melanoma: Safety Run-in and Biomarker Cohorts of COMBI-I","volume":"26","author":"Dummer","year":"2020","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Healthcare Interventions: Explanation and Elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12967-020-02209-y","article-title":"Updated Data From IMPemBra, a Phase 2 Study Comparing Pembrolizumab (PEM) With Intermittent\/Short-Term Dual MAPK Pathway Inhibition (Mapki, Dabrafenib + Trametinib, D + T) Plus PEM in Patients Harboring the BRAFV600 Mutation","volume":"18","author":"Rozeman","year":"2020","journal-title":"J Trans Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2273","article-title":"Spartalizumab Plus Dabrafenib and Trametinib (Sparta-DabTram) in Patients (pts) With Previously Untreated BRAF V600\u2013Mutant Unresectable or Metastatic Melanoma: Results From the Randomized Part 3 of the Phase III COMBI-I Trial","volume":"31","author":"Nathan","year":"2020","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","article-title":"Updated Guidance for Trusted Systematic Reviews: A New Edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying Heterogeneity in a Meta-Analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e001806","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 Part 3: A Randomized, Double-Blind, Phase 2 Study of Pembrolizumab, Dabrafenib, and Trametinib in BRAF-Mutant Melanoma","volume":"8","author":"Ferrucci","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, Vemurafenib, and Cobimetinib as First-Line Treatment for Unresectable Advanced BRAF(V600) Mutation-Positive Melanoma (Imspire150): Primary Analysis of the Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.1038\/s41467-020-19810-w","article-title":"Pd-L1 Blockade in Combination With Inhibition of MAPK Oncogenic Signaling in Patients With Advanced Melanoma","volume":"11","author":"Ribas","year":"2020","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0253","article-title":"Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients","volume":"25","author":"Ives","year":"2007","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919830826","article-title":"Combined Targeted Therapy and Immunotherapy in Melanoma: A Review of the Impact on the Tumor Microenvironment and Outcomes of Early Clinical Trials","volume":"11","author":"Pelster","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved Antitumor Activity of Immunotherapy With BRAF and MEK Inhibitors in BRAF(V600E) Melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2248","article-title":"Clinical Outcomes of BRAF Plus MEK Inhibition in Melanoma: A Meta-Analysis and Systematic Review","volume":"8","author":"Yu","year":"2019","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15632","article-title":"Efficacy and Safety of BRAF Inhibition Alone Versus Combined BRAF and MEK Inhibition in Melanoma: A Meta-Analysis of Randomized Controlled Trials","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association Between Immune-Related Side Effects and Efficacy and Benefit of Immune Checkpoint Inhibitors - A Systematic Review and Meta-Analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.732","article-title":"Targeting Immune Checkpoints in Unresectable Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis of Anti-CTLA-4 and Anti-PD-1 Agents Trials","volume":"5","author":"Yun","year":"2016","journal-title":"Cancer Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0474-7","article-title":"Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF-mutated Melanoma Patients","volume":"25","author":"Sullivan","year":"2019","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1238557","DOI":"10.1080\/2162402X.2016.1238557","article-title":"Targeting the MAPK and PI3K Pathways in Combination With PD1 Blockade in Melanoma","volume":"5","author":"Deken","year":"2016","journal-title":"Oncoimmunology"},{"key":"B37","unstructured":"Open Label, Multicentre Study of Encorafenib + Binimetinib + PD (Programmed Cell Death Protein) -1 Antibody Pembrolizumab.2016"},{"key":"B38","unstructured":"Neoadjuvant Dabrafenib, Trametinib and\/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma.2016"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.693655\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T08:50:53Z","timestamp":1623660653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.693655\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":38,"alternative-id":["10.3389\/fonc.2021.693655"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.693655","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"article-number":"693655"}}